The Concept

bio-sourLaboratory glass 0c87a44

The bioprocessing industry has undergone several changes over the past few years starting from the development of better expression systems to modular and flexible manufacturing facilities including the emergence and use of disposables. However, there is a need for higher productivity when it comes to upstream, need for efficient process development and cost-effective and alternative techniques when it comes to downstream processing. This apart, the industry also handles specific issues on designing facilities for flexibility and in the wake of multiple products.

The biologics industry in Korea is estimated to be the fastest growing market in the world. Recently, Samsung Biologics headquartered in Korea expects to become the world’s largest biologics contract manufacturing organization (CMO) with a total production capacity of 360,000 liters.

The key drivers driving the growth of the biologics industry in Korea are new- cell culture techniques, fast-track GMP facilities, flexible manufacturing facilities using disposables, attempts for continuous manufacturing, combining modular facilities and single-use and other advances in the downstream processing of biologics. However, the factors hindering the growth of the biopharmaceutical industry mainly are from the bioprocessing side including high-manufacturing complexities, expensive purification processes and other challenges across the bioprocessing value chain.

8th Annual Biologics Manufacturing Korea, therefore, aims to provide a neutral platform to address the challenges faced in this sector including:

  • Reducing the timelines and need for efficient screening technologies and monitoring bioprocesses in order to reduce timelines for upstream bioprocesses.
  • Incorporating QbD in the early process development.
  • Technical and economic viability of using a single-use biomanufacturing facility.
  • Development of robust processes to suit evolving biomanufacturing needs.
  • Purification process development to maximize process economy.
  • Challenges in the downstream purification for highly complex molecules.
  • Designing ad automating quality control challenges during scale-up and process change.
  • Observations in the use of disposables vs hard-piped steel containers.
  • Perceived barriers to switch over from Batch to continuous manufacturing.
  • Future of continuous manufacturing and the challenges faced by companies planning for the paradigm shift.

With a strategic location- Korea, best manufacturing facilities, strong government support, easy access from all Asian countries, technological leadership and the house of top biopharmaceutical companies developing smart manufacturing facilities for the production of biologic drugs,  South Korea will indeed be an important and bright spot for such an exciting gathering.

Join us in Korea in the foremost bioprocessing industry gathering in Seoul this year.

IMAPAC_001

To explore your speaking engagement at 8th Annual Biologics Manufacturing Korea 2019, please contact:

Joanna Lim      
Conference Producer

T. (65) 3109 0131
E. joanna.lim@imapac.com

Silver Sponsors

Silver Sponsors

Associate Sponsors

Associate Sponsors

Exhibitors

Exhibitors

Media Partners

Media Partners